MRSN – mersana therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Alphina Therapeutics Strengthens Management Team with Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer [Yahoo! Finance]
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
Form SCHEDULE 13G/A Mersana Therapeutics, Filed by: Nextech Crossover I GP S.a r.l.
Form SCHEDULE 13G/A Mersana Therapeutics, Filed by: EcoR1 Capital, LLC
Form 4 Mersana Therapeutics, For: Dec 19 Filed by: EcoR1 Capital, LLC
Form 8-K Mersana Therapeutics, For: Dec 19
Form SC 13D/A Mersana Therapeutics, Filed by: Bain Capital Life Sciences Fund II, L.P.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.